RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
To analyze the correlations of cluster of differentiation 24 (CD24), B7-H4 and proliferating cell nuclear antigen (PCNA) with clinicopathological indexes of ovarian cancer by detecting the expressions of the three indexes, and further explore the clinical value of CD24, B7-H4 and PCNA detection in early diagnosis of ovarian cancer and screening of high-risk patients. Gynecological paraffin-embedded blocks archived in the Department of Pathology of Suzhou Municipal Hospital from January 2015 to June 2017 were selected. There were 30 patients with benign epithelial ovarian tumor and 50 patients with malignant tumor according to the medical history and pathological data. In addition, 20 patients with normal ovarian tissues were enrolled as controls. Immunohistochemical streptavidin-peroxidase (SP) method was applied to detect CD24, B7-H4 and PCNA in different ovarian tissues, which were ultimately analyzed in combination with clinicopathological factors such as grade of differentiation and with or without lymph node metastasis. The expression levels of CD24, B7-H4 and PCNA in ovarian cancer tissues were remarkably higher than those in benign ovarian tumor tissues and normal ovarian tissues, and the expression levels of the three indexes in poorly- and moderately-differentiated ovarian cancer were notably higher than those in well-differentiated ovarian cancer (p<0.05). The expressions of CD24, B7-H4 and PCNA in ovarian cancer tissues with lymph node metastasis were significantly increased compared with those in ovarian cancer tissues without lymph node metastasis (p<0.05). The expressions of CD24, B7-H4 and PCNA in ovarian cancer tissues were positively correlated with each other (p<0.05). The expressions of CD24, B7-H4 and PCNA have correlations with the occurrence, development, invasion and metastasis of ovarian cancer, and the combined detection may have clinical guiding significance for early diagnosis of ovarian cancer and screening of high-risk patients.